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Review
Sudden death: Neurogenic causes,
prediction and prevention
Nina Japundzˇic´-Zˇigon1, Olivera Sˇarenac1, Maja Lozic´1,
Marko Vasic´1, Tatjana Tasic´1, Dragana Bajic´2, Vladimir Kanjuh3
and David Murphy4
Abstract
Sudden death is a major health problem all over the world. The most common causes of sudden death are cardiac but
there are also other causes such as neurological conditions (stroke, epileptic attacks and brain trauma), drugs, catechol-
amine toxicity, etc. A common feature of all these diverse pathologies underlying sudden death is the imbalance of the
autonomic nervous system control of the cardiovascular system. This paper reviews different pathologies underlying
sudden death with emphasis on the autonomic nervous system contribution, possibilities of early diagnosis and prognosis
of sudden death using various clinical markers including autonomic markers (heart rate variability and baroreflex
sensitivity), present possibilities of management and promising prevention by electrical neuromodulation.
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Introduction
Sudden death (SUD) is a major health problem all over
the world. Estimations are that SUD is responsible for
one ﬁfth of all deaths. The most common causes of
SUD are cardiac, but there are also non-cardiac rea-
sons, such as neurogenic conditions, catecholamine tox-
icity, asthma attacks etc.1 The diversity of underlying
pathology of SUD is the reason why there is neither
accurate prediction nor eﬀective management. Yet, a
plethora of data suggests that the imbalance of the
autonomic nervous system control of the cardiorespira-
tory system is a common phenomenon linking various
pathologies underlying SUD syndrome.
Two components of the autonomic nervous system,
the sympathetic and parasympathetic (vagal), act in
concert to modulate electrical and mechanical proper-
ties of the heart. The balance between the two is ﬁne-
tuned by the brain, which processes the inputs from the
periphery (baro-reﬂexes, chemo-reﬂexes, etc.) and
higher brain structures (cortex, limbic system, hypo-
thalamus, etc.). Postganglionic sympathetic nerves
that reach the heart release noradrenalin and activate
b adrenergic receptors (b1<<b2<b3) to produce
the following eﬀects: synthesis of adenylate cyclase,
formation of cyclic adenosine monophosphate and acti-
vation of protein kinase A. Protein kinase A then phos-
phorylates structural proteins of ion channels (Naþ, L
type Caþþ, ultra rapid and slow delayed rectiﬁer Kþ)
and key proteins involved in intracellular calcium hand-
ling (phospholamban, troponin I, ryanodine type 2
receptors, etc.) endorsing arrhythmogenesis under
unfavourable, pathological conditions. On the other
hand, vagal nerves that innervate the heart most den-
sely in atria release acetylcholine that binds to muscar-
inic, M-2 receptors coupled to inhibitory G proteins,
activates Kþ channels and inhibits cyclic adenosine 30,
50-monophosphate-dependent stimulation of L type
Caþþ channels. Cholinergic transmission is further
supported by nitric oxide release from cardiac nerves
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further preventing the occurrence of life-threatening
arrhythmias.1,2
Heart diseases aﬀect its architecture and the
response to neuro-endocrine control mechanisms.
They also incite deleterious adaptive remodeling of
mechanisms leading to a fatal outcome. Thus the pur-
pose of the present paper is to update knowledge on the
neurogenic contribution to the pathogenesis of SUD,
the possibilities of early diagnosis/prognosis and pre-
sent and future directions of prevention. MEDLINE/
Pubmed, Web of science, EMBASE and CENTRAL
databases were searched for relevant papers on SUD
syndrome and the autonomic nervous system.
Causes of SUD
Cardiac causes
The vast majority of the cases of SUD occur in the
elderly population suﬀering from cardiac diseases, of
which coronary artery disease is the most prevalent.
Frequent cardiac diseases associated with SUD also
include cardiomyopathies (both hypertrophic and
dilated forms) and congestive heart failure.3,4
Accumulated evidence suggests that neurogenic dys-
function is central to the development and progression
of most cardiovascular diseases including myocardial
infarction (MI) and heart failure, and that enhanced
sympathetic activity and impaired cardiac parasympa-
thetic responsiveness are negative prognostic indicators
for both morbidity and mortality associated with
SUD.5
During cardiac ischaemia, sympathetic hyperactivity
is crucial for the generation of spontaneous ventricular
ectopy and life-threatening arrhythmias.6 In the past
few decades the mechanisms have been elucidated.
Cardiac ischaemia has been shown to injure both
nerves and myocardial tissue and to elicit denervation
and re-innervation of the myocardium, as advocated by
sympathetic scintigraphy.7 Acute ischaemic necrosis
induces sympathetic denervation and the upregulation
of b adrenergic receptors at cardiomyocytes inducing
receptor hypersensitivity8 and hyperresponsiveness to
catecholamines. Moreover, in the infarcted area,
nerve growth factor (NGF) is released locally in abun-
dance and this triggers increased expression of NGF
and of growth associated protein 43 (GAP43). These
are transported retrogradely to the left stellate ganglion
where they induce nerve sprouting in non-infarcted
sites.9,10 Uneven sympathetic innervations of the myo-
cardium, and release of neurotransmitters (noradre-
nalin, neuropeptide Y) in hyper-innervated sites in
excess,11 induce ionic imbalance and action potential
prolongation that increases the risk of arrhythmias
and the incidence of SUD.12
Ischaemic and other causes of cardiomyopathy, such
as infection (usually viral), drug toxicity (mostly
antarcycline cytotoxicity), inﬂammation, autoimmune
diseases, and transmissible gene mutations (mostly
genes encoding sarcomeric proteins, nuclear envelope
and the cytoskeleton) are associated with the formation
of scars and ﬁbrosis. Histological studies identiﬁed two
forms of ﬁbrosis: replacement ﬁbrosis due to cell death
and interstitial ﬁbrosis due to collagen accumulation,
both of which are governed by the activation of the
renin–angiotensin system and b adrenergic system.13
Areas of interstitial ﬁbrosis slow or block electrical
conduction and its peripheral zone is thought to act
as a node for re-entry wave fronts.14,15
Regardless of the cause of heart failure (ischaemic,
non-ischaemic), the reduction of cardiac output triggers
a reﬂex increase of sympathetic outﬂow, as well as an
increase of renin–angiotensin–aldosterone synthesis
and the release of antidiuretic hormone from the hypo-
thalamus, in order to maintain the circulation.16
Increased sympathetic activity directed to the failing
heart increases heart rate (HR) and causes diastolic cal-
cium leak through ryanodine type 2 (RyR2) receptors.
Focally released calcium initiates more calcium release
and propagates as a calcium wave that can cause
delayed afterdepolarisation and engender premature
beats evolving to sustained ventricular tachycardia.17
The neuroendocrine arousal in congestive heart failure
incites adaptive but harmful mechanisms, NGF down-
regulation, reduction of sympathetic innervations18 and
downregulation of b adrenergic receptors.19 Loss of
adrenergic support is detrimental to the heart inotrop-
ism. An alternative scenario was observed in an experi-
mental model of the right ventricular hypertrophy
induced by monocrotaline-induced pulmonary hyper-
tension in rats by Kimura and colleagues.20 In that
model, in spite of the NGF upregulation and sympa-
thetic hyper-innervation, there was a decrease of
noradrenalin synthesis and re-uptake suggesting func-
tional denervation occurs due to nerve rejuvenation.21
The experimental ﬁndings on the role of the sympa-
thetic nervous system in the occurrence of life-threaten-
ing arrhythmias is clearly supported by the eﬃcacy
of b-blockers in the prevention of SUD in patients suf-
fering from MI, as well as the eﬀectiveness of cardiac
sympathetic denervation in patients suﬀering from
ventricular tachycardia and ﬁbrillation storms refrac-
tory to drug treatment.22
A very small percentage (less than 1%) of the total
population aﬀected by SUD are young people, below
the age of 35 years.23 At autopsy, usually no morpho-
logical abnormalities are identiﬁed and the underlying
cause of SUD remains uncovered. Molecular forensic
pathology revealed that the population of young people
that succumbed to fatal arrhythmias is aﬀected by
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hereditary, genetic, disorders caused by mutations in
genes encoding structural elements of cardiac ion chan-
nels responsible for abnormal electrical activity of the
heart.24 There is no doubt that the autonomic activity
associated with exercise and stress can trigger SUD in
individuals suﬀering from congenital channelopathies,
usually presenting normal ECG under baseline physio-
logical conditions. The most common hereditary
disorders are congenital long QT syndrome (LQTS),
catecholaminergic polymorphic ventricular tachycardia
(CPVT) and Brugada syndrome (BrS).
Congenital LQTS is characterised by delayed repo-
larisation of the myocardium and is genetically a het-
erogeneous disorder. It is often inherited in an
autosomal dominant mode. Hundreds of mutations
have been identiﬁed in 13 genes including KCNQ1
(LQT1), hERG (LQT2), SCN5A (LQT3), ANK2
(LQT4), KCNE1 (LQT5), KCNE2 (LQT6), KCNJ2
(LQT7), CACNA1C (LQT 8), CAV3 (LQT9), SCN4B
(LQT10), AKAP9 (LQT11), SNTA1 (LQT12) and
GIRK (LQT13).25 Among these, the chromosome 7
associated hERG (human ether-a`-go-go-related gene,
alternative nomenclature KCNH2) mutation was the
ﬁrst reported and is the most prevalent.26,27 This gene
encodes the constitutive a subunit of voltage-gated Kþ
channels (Figure 1). The a subunit forms the conduct-
ance pore of the voltage-gated Kþ channel and the
mutations change modulates its voltage dependence.28
To date, nearly 300 diﬀerent hERG mutations linked to
LQT2 have been identiﬁed. Such mutations may cause
loss of hERG function by one of four main eﬀects:
reduced or defective synthesis; defective traﬃcking
from the endoplasmic reticulum to the plasma mem-
brane (resulting in decreased surface expression);
defective gating; or defective ion permeation.29
The hERG Kþ channel is responsible for ‘rapid’
delayed rectiﬁer Kþ current, which plays an important
role in ventricular repolarisation. Its malfunction is
associated with prolongation of the QRST interval.
Long QRST reﬂects the prolongation of the phase 3
action potential representing the process of cardiac
cell repolarisation. As repolarisation becomes pro-
longed, the left ventricle becomes susceptible to a pre-
mature (i.e. early) afterdepolarisation, which triggers
rapid polymorphic ventricular tachycardia ‘torsades
de pointes’, the phenomenon ﬁrst described by French
physician Franc¸ois Dessertenne in 1960s. The name
denotes the twisting of the points of QRS complexes
around the isoelectric baseline of the ECG.
CPVT is another heritable arrhythmia syndrome
transmissible in autosomal recessive manner, as a
result of mutations of genes encoding RyR2 (CPVT1
60%) cardiac ryanodine receptor,30 or a rare form with
mutations of cardiac calsequestrin encoded by the
CASQ2 gene (CPVT2). Calsequestrin is a protein in
the endoplasmatic reticulum that binds calcium and
releases it during depolarisation-associated calcium-
induced calcium release. Mutations of the CASQ2
gene disrupts the linear polymerisation of the calseques-
trin and reduces its ability to retain calcium inside the
reticulum. It is usually diagnosed during exercise or
stress by the appearance of ventricular ectopy typically
clinically manifested with syncope or SUD.31
BrS is in 30% of cases inherited as an autosomal
dominant trait cause by loss-of-function mutation of
the SCN5A gene that encodes cardiac sodium channel
(BrS1).24 At rest, ECG records of the precordial V1–V3
leads show elevation of the ST segment and negative T
wave. They have an increased risk of episodes of poly-
morphic ventricular tachyarrhythmia leading to SUD.
It is noteworthy mentioning that the LQTS and tor-
sades de pointes can be acquired and induced by drugs,
both cardiac (class I and class III anti-arrhythmics) and
non-cardiac drugs (treatments for widely diﬀering con-
ditions).32–35 The mechanism of drug-induced arrhyth-
mias seems to involve direct blockade of the hERG Kþ
channel or inhibition of hERG traﬃcking.36 Knowing
this, an in-vitro IKr/hERG assay using the patch clamp
technique has been adopted for early screening of drug
candidates in a cardiac safety testing programme. 36,37
Figure 1. Alpha subunit of the voltage operated Kþ channel.
The voltage operated Kþ channel is a symmetric tetramer of four
alpha subunits around a pore. Each a subunit encoded by the
human ether-to-go-go gene (hERG) has six transmembrane
helices.
Japundzˇic´-Zˇigon et al. 31
Also, in clinical settings a risk score for predicting QTc
prolongation has been proposed and validated.38,39
Neurocardiogenic causes
In 1942, the famous professor of physiology at Harvard
Medical School, Walter B. Cannon, published a paper
entitled ‘Voodoo Death’ largely known as death from
fright.40 Cannon postulated that, under special circum-
stances involving social pressure and susceptible psy-
chological proﬁle, death can occur from fright in an
otherwise healthy person. He believed that fright can
elicit intense activation of the sympatho-adrenal
system.41 His student Curt Richter challenged his
view with evidence that showed that increased vagal
tone, without sympatho-adrenergic activation, pro-
voked massive SUD in a colony of rodents whose whis-
kers were clipped.42 It is now established that the
sympathetic and parasympathetic part of the auto-
nomic nervous system complements each other in car-
diovascular regulation and that life-threatening
stressors induce sympathovagal imbalance.43
In the 1970s, clear experimental evidence that car-
diac lesions can be produced as a result of nervous
system disease was provided. Hans Selye was the ﬁrst
to produce heart injury in rats by exposing them to
stressors and increased concentrations of hormones.44
In these animals thrombotic coronary occlusion was
not present, and the pattern of myocardial necrosis
described by Selye was coagulative myocytolysis
whereby myocytes die in a hypercontracted state with
early myoﬁbrillar damage and irregular cross-band for-
mation (also termed myoﬁbrillar degeneration and con-
traction band necrosis). Lesions were multifocal, and
the localisation was preponderantly subendocardial,
corresponding to the distribution of sympathetic
nerve endings. A conﬁrmation for the deleterious eﬀects
of excessive adrenergic activation on the heart came
from the rat model for stress-induced cardiomyopathy.
Infusion of high doses of isoprenaline, a b adrenergic
receptor agonist, has been shown to induce injury of
the rat heart, pointing to a major role of b adrenergic
receptors in catecholaminergic cardiotoxicity.45
Figure 2 illustrates akinetic parts of the myocardium
of a rat treated with a high dose of isoprenaline.
Decades later, neurocardiogenic heart injuries were
reported in humans, giving clinical conﬁrmation to the
experimental ﬁnding. Acute cardiomyopathy known as
broken heart syndrome or Takotsubo cardiomyopathy
was ﬁrst described by Japanese cardiologists46 towards
the end of the 20th century in the Japanese population.
It aﬀected elderly women who experienced great
grief. It is clinically indistinguishable from acute coron-
ary syndrome. However, it is not associated with
coronary thrombosis and the pathognomonic sign at
echocardiography is apical ballooning (akinetic part)
of the left ventricle resembling the shape of a ‘tako-
tsubo’ ceramic pot used to trap octopus in Japan.47
Further clinical evidence for neurocardiogenic injuries
came from patients suﬀering from pheochromocytoma,
in which chronic exposure to increased concentrations
of circulating catecholamines was evident.48 Multifocal
subendocardial injuries were also observed in reperfu-
sion injuries during heart transplantation, so-called
‘stoned heart syndrome’, as well as during percutaneous
coronary intervention.49 In past decades advances have
been made in understanding these mechanisms but not
yet in providing eﬀective cardioprotection.50
Cardiac lesions produced by central nervous system
stimulation are morphologically indistinguishable from
stress and catecholamine-induced cardiac damage.
Back in 1963, Melville and colleagues51 produced
bradycardia and myocardial necrosis in cats by stimu-
lation of the anterior hypothalamus. Later on, Kannan
and collaborators52 in 1989 induced an increase in
blood pressure (BP) and renal sympathetic outﬂow in
conscious rats by bilateral electrical stimulation of the
paraventricular nucleus (PVN) of the hypothalamus or
by microinjecting L-glutamate, an excitatory amino
acid neurotransmitter, into the PVN. Morphological
studies complemented functional studies and provided
evidence of direct PVN axonal connections, from the
parvocellular part to the respiratory, pre-Bo¨tzinger
complex, vasomotor and cardiac neurons in the rostro-
ventro-lateral medulla and preganglionic neurons in the
inter-medio-lateral column of the spinal cord. The PVN
also receives abundant inputs from other part of the
hypothalamus, the limbic system and higher brain
regions as well as from the periphery.53 Such neural net-
work enables the PVN to be a key site in the coordin-
ation of behavioural and neuroendocrine response to
stress. Furthermore, it has been assumed, both in ani-
mals and humans, that the increase of L-glutamate con-
centrations in the cerebrospinal ﬂuid during cerebral
Figure 2. Isoprenaline-induced cardiac dysfunction. (a)
Parasternal long axis image at end-systole showing typical akin-
esia of left ventricular septal wall in one male Wistar rat two
hours after 50 mg/kg isoprenaline injection. (b) M mode of long
axis view. Dotted circle and arrows indicate akinetic parts of
myocardium Source: reproduced with permission of M. Vasic´.
32 European Journal of Preventive Cardiology 25(1)
ischaemia stimulatesN-methyl-D-aspartic acid receptors
in PVN and enhances sympathetic drive to the heart54–57
suggesting a mechanism of SUD associated with stroke.
The PVN is a major source of vasopressin and oxytocin
and vasopressin receptors (V) and oxytocin receptors
(OT) are found in abundance in the PVN.58 Their role
is to prime magnocellular neurons and also to integrate
the activity of neurons located in the magnocellular and
the parvocellular parts of the PVN,59 involved respect-
ively in humoral and autonomic neural control of the
circulation.60 Lozic´ and colleagues61,62 have demon-
strated that upregulation of vasopressin V1A and OT
receptors in PVN modulates autonomic control of the
cardiovascular system and changes the vulnerability of
the rat phenotype to stress, thus pointing to possible
targets for new drug development in cardioprotection
from neurocardiogenic injuries.
In clinical practice arrhythmias are frequently seen
in stroke patients without primary heart disease,63 and
their occurrence correlates to a central increase of sym-
pathetic activity.64 Other brain regions aﬀected by
stroke have also been associated with sudden auto-
nomic death. Oppenheimer suggested a role for the insu-
lar cortex in the pathophysiology of SUD.65 It has been
reported that right-sided ventromedial prefrontal
cortex lesions bear a risk of an exaggerated cardiovas-
cular response.66 Myocardial damage and an increase
of troponins and Takotsubo syndrome have been
reported in humans suﬀering from epileptic seiz-
ures.67–69 McMillan and Teasdale70 reported a high
incidence of sudden death in humans who had mild
traumatic brain injury years ago. Clinical evidence of
neurocardiogenic damage is usually reported in antero-
lateral and inferolateral leads of the ECG recording:
repolarisation changes in ST segment, peaked T wave
and U wave, known as hyperkalemic pattern.64
Markers of SUD
Patients at greatest risk for SUD are those with coron-
ary artery disease and impaired left ventricular func-
tion, heart failure secondary to ischaemia or
idiopathic dilated cardiomyopathy, hypertrophic car-
diomyopathy, documented sustained ventricular tachy-
cardia or ﬁbrillation, and survivors of cardiac arrest.
Assessing the cardiovascular function and the degree
of impairment of left ventricular ejection fraction
(LVEF) is currently used for prognosis in patients
with structural heart disease. It is acknowledged that
a LVEF of 40% or less is an independent risk factor.
However, it should be noted that there is no linear
correlation between the degree of left ventricular dys-
function and the prevalence of fatal arrhythmias, the
occurrence of which is higher among patients with mid
to moderate heart failure, rather than in those with
severe failure.71 Therefore, multifaceted evaluation
using diﬀerent risk markers increases the accuracy of
detecting cardiac risk for life-threatening arrhyth-
mias.71,72 Electrocardiographic measures such as stand-
ard 12-lead ECG QRS duration, QT dispersion, signal
averaged ECG, microvolt-level T wave alternans (a
beat-to-beat variability of T wave amplitude that
reﬂects heterogeneity/dispersion of ventricular repolar-
isation), HR turbulence and HR deceleration capacity,
have all been proposed.73 In electrophysiological test-
ing, a programmed ventricular stimulation is used for
risk stratiﬁcation. Induction of sustained ventricular
tachycardia during programmed ventricular stimula-
tion is a marker of increased risk of recurrent sustained
ventricular tachycardia and sudden cardiac death.74
Among autonomic markers the most appreciated
that add to the speciﬁcity of LVEF are heart rate
variability (HRV) and baroreﬂex sensitivity (BRS).
The clinical relevance of HRV was ﬁrst observed in
1963 by Hon and Lee,75 but it became recognised in
the late 1980s when it was conﬁrmed that HRV is a
strong and independent predictor of mortality after
MI.76–78 Many methods in both the time and frequency
domain are used to calculate HRV as detailed
elsewhere.79 However, the true nature of HRV was dis-
covered by the method of spectral analysis in animal
models.80 In animals and humans, the lower frequen-
cies of the power spectrum of HRV are created by the
activity of the sympathetic nervous system directed to
the heart, whereas higher frequencies are created by
vagal activity modulated by respiration and depict
respiratory sine arrhythmia.80,81 In elderly individuals,
the lower frequency components of the HR spectrum
are observed because respiratory sine arrhythmia is lost
with ageing.82 In diseased individuals, in patients sur-
viving an acute MI and in patients suﬀering from
chronic heart failure or left ventricular dysfunction,
reduced or abnormal HRV are indicators of an
increased risk of mortality within a few years after
an acute MI or after a diagnosis of congestive heart
failure or left ventricular dysfunction.5,83–85 HRV has
proved to be useful in predicting SUD in patients
suﬀering from non-cardiac causes.69,86 Picturesque
methods for the assessment of HRV are colour spec-
trograms (Figure 3) and Poincare´ plots (Figure 4).
When the non-linearity of the HR signal is increased,
the reliability of linear methods is reduced, and add-
itional insight is provided using non-linear parameters.
Complexity-based analysis of fractal dimension and
approximate entropy of HRV increase the accuracy
of risk stratiﬁcation. They were also proved to be
useful in predicting the risk in Takotsubo cardiomy-
opathy.87 HRV and BP variability have been used
for the assessment of preclinical drug safety for
drug-induced cardiotoxicity.88–90
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The baroreﬂex is the main negative feedback correc-
tor of arterial BP, and evaluation of BRS is an estab-
lished tool for the assessment of autonomic control of
the cardiovascular system.91 Baroreceptors located in
the upper part of the body, aortic arch and carotid
sinuses sense subtle changes in central BP and adjust
circulation to all organs, but especially to the brain, on
a beat-to-beat basis. The more sensitive the baroreﬂex,
the less variable is the BP, and the lower is the risk
of stroke.92 Under physiological conditions, BRS
decreases during exercise and stress,93,94 in order to
permit concomitant increase of arterial BP and HR to
supply adequate circulation to the body. However, a
decrease in BRS occurs in disease, in survivors of MI
and in patients suﬀering from chronic heart failure, and
represents an independent risk factor for SUD.5,91
BRS can be assessed in an old fashioned manner
using pharmacological tools (Oxford method) and
using novel methods from spontaneously occurring
BP and pulse interval variability in the low frequency
and high frequency spectral bands. The Oxford method
requires injections of short-acting vasoconstrictor or
vasodilating drugs to trigger a reﬂex HR response,
but this carries serious risks for the patient and is
thus not widely used in clinical practice. However, the
sequence method assesses the BRS from spontaneously
and concomitantly occurring systolic BP and pulse
interval increasing/decreasing values,95 thus circumvents
the use of drugs and is without risk for patients, so may
be applicable in wide populations. Several useful param-
eters have been proposed to evaluate the function of the
spontaneous baroreﬂex. Experimental evidence indicates
that an increase in spontaneous BRS over an increase in
operating range indicates allostatic overload and may
precede the exhaustion of the neurogenic mechanisms.94
Possibilities of SUD prevention
The current management of SUD involves drugs
and electrical devices for correction of arrhythmias.
In patients with ischaemic heart disease and congestive
heart failure b-blockers were found to be most eﬀective
and reduced total mortality. Other anti-arrhytmic
drugs are not well tolerated because they have pro-
arrhythmogenic action. Class I anti-arrhythmic drugs
in patients with ischaemic heart disease, especially
class 1C, have been shown to increase mortality.
Class III, dofetilide and amiodarone have no eﬀect on
mortality while d-sotalol increases mortality.96 A new
drug, dronedarone, is promising.97 b-Blockers have
been applied with success in women suﬀering from her-
editary long QT syndrome, in the postpartum period
when the risk from cardiac events is several fold
increased.98 In the therapy of coronary artery disease
and congestive heart failure the so-called non-anti-
arrhythmic drugs are useful in the prevention of
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Figure 3. Spectrograms of heart rate variability (HRV) in cardiomyopathy induced by doxorubicin (right). Note the reduction of HRV
in lower frequencies (marked in red) by toxic doses of doxorubicin three days before fatal outcome. Source: reproduced with
permission of D. Bajic´.
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SUD, although their eﬀect is indirect and delayed.
These include angiotensin-converting enzyme inhibitors
and angiotensin II AT1 receptor blockers, statins, and
nutrients such as ﬁsh oil.98
In patients with very low LVEF, asymptomatic ven-
tricular arrhythmias and inducible ventricular tachycar-
dia/ﬁbrillation, an implantable cardioverter-deﬁbrillator
(ICD) is superior to conventional drug therapy. In sec-
ondary prevention of SUD, in patients with sustained
ventricular tachycardia/ﬁbrillation or survivors of
sudden cardiac death drug treatment alone is ineﬀective
and can be used as an adjunct to ICD to decrease epi-
sodes of ventricular tachycardia/ﬁbrillation and non-sus-
tained ventricular tachycardia to reduce ICD discharge,
to slow the rate of ventricular tachycardia and to
increase haemodynamic stability.96,99
Patients with advanced heart failure and low LVEF
in which symptoms progress despite optimal pharma-
cotherapy and ICD device implantation may beneﬁt in
future from devices engineered to restore sympathova-
gal balance to the heart by electrical neuromodulation.
Several options have been investigated in animal
models, involving baroreﬂex activation therapy (BAT)
and vagal stimulation. In dogs with experimentally
induced heart failure and very low LVEF, BAT reduced
sympathetic tone and enhanced vagal tone, reduced
susceptibility to life-threatening arrhythmias and pro-
longed survival.100 The ﬁrst-into-man study, although
performed on a small sample and with a short follow-
up period conﬁrmed the beneﬁcial eﬀects of BAT in
advanced stages of chronic heart failure.101 In the ﬁrst
randomised and controlled trial patients with heart fail-
ure with reduced ejection fraction also beneﬁted from
BAT treatment.102 An alternative approach to restore
the sympathovagal balance to the heart is to stimulate
the vagus nerve directly. Experimental studies indicate
that several mechanisms are likely to be involved in the
beneﬁcial eﬀect of vagal stimulation.103 These include
anti-adrenergic eﬀects, anti-apoptotic eﬀects, an
increase of nitric oxide synthesis and anti-inﬂammatory
eﬀects.104 The ﬁrst-in-man study with chronic heart
failure conﬁrmed that the method is safe and well tol-
erated, and signiﬁcant improvement of the LVEF and
life quality was observed.105 There are experimental
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with doxorubicin. Note the comet-shaped plot before treatment and the change of the shape after treatment due to a reduction of
HR variability three days before fatal outcome. Source: reproduced with permission of D. Bajic´.
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indices in rabbit and rats that BRS may be increased by
chronic exposure of baroreceptors to a medium inten-
sity static magnetic ﬁeld.106 Studies indicate that a
medium intensity static magnetic ﬁeld aﬀects BRS
and cardiovascular haemodynamics by modulating
microcirculation, neurotransmission and the rate of bio-
chemical reactions.107
Finally, it can be concluded that in spite of the devel-
opment of new anti-arrhythmic drugs and DCI devices,
SUD remains a frequent cause of death worldwide.
In the past few decades progress has been made in the
multifaceted risk stratiﬁcation approach by the intro-
duction of autonomic markers into clinical practice.
A new approach of treatment by electrical neuromodu-
lation is under development for the prevention of SUD
in advanced stages of congestive heart failure. The
results of large scale clinical studies are still awaited
to conﬁrm the clinical eﬃcacy and tolerability of elec-
trical neuromodulation that may hopefully become
a new cornerstone in the prevention of SUD in
these patients.
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